Reported Earlier, Disc Medicine Reports 61.5% Of RESTORE-PV Cohort A Patients Remained Phlebotomy-Free Through 26 Weeks On DISC-3405
Share
Why It Matters
A medicine company's new drug kept most patients in their test study from needing blood removal for six months. When a medicine works well in early tests, it hints the company might have a real solution that doctors will want.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.